Seeing Is Believing
Currently out of the existing stock ratings of David Westenberg, 131 are a BUY (62.38%), 73 are a HOLD (34.76%), 6 are a SELL (2.86%).
Analyst David Westenberg, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 56.25% that have a potential upside of 18.36% achieved within 115 days.
David Westenberg’s has documented 425 price targets and ratings displayed on 23 stocks. The coverage is on Healthcare, Financial Services sectors.
Most recent stock forecast was given on NTRA, Natera at 15-May-2025.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2023. The price target of $3 was fulfilled within 1 day with a profit of $0.24 (8.7%) receiving and performance score of 86.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$23
$3.73 (19.36%)
$16
2 months 11 days ago
(05-May-2025)
4/13 (30.77%)
$4.18 (22.21%)
82
Hold
$27
$7.73 (40.11%)
$25
11 months 12 days ago
(04-Aug-2024)
1/6 (16.67%)
$3.33 (14.07%)
156
Buy
$125
$105.73 (548.68%)
$141
3 years 5 months 22 days ago
(24-Jan-2022)
3/7 (42.86%)
$61.5 (96.85%)
87
Sell
$65
$28.11 (76.20%)
$55
3 years 11 months 6 days ago
(10-Aug-2021)
6/8 (75%)
$-21.64 (-24.36%)
252
Buy
$140
$120.73 (626.52%)
$140
3 years 11 months 7 days ago
(09-Aug-2021)
6/9 (66.67%)
$42.66 (43.83%)
90
Which stock is David Westenberg is most bullish on?
Which stock is David Westenberg is most reserved on?
What Year was the first public recommendation made by David Westenberg?